Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Reuters

Jun 25

Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546217559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546217559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546217559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546217559","market":"fut","top_or_hot":-1,"title":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-25 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRA","symbol_name":"Mira Pharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL99FqMP:1","article_id":"2546217559","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546217559","pubTimestamp":1750852827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1. Mira Pharmaceuticals Inc.  has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRA":"Mira Pharma","BK4007":"制药"},"translate_title":"Mira Pharmaceuticals Inc.正在等待监管部门批准收购SKNY Pharmaceuticals，旨在通过SKNY-1彻底改变减肥和戒烟市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    \n\n        Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}